|
|
 Previous Article | Table of Contents | Next Article 
Randomized Trial of Autologous Filgrastim-Primed Bone Marrow Transplantation Versus Filgrastim-Mobilized Peripheral Blood Stem Cell Transplantation in Lymphoma Patients
Daniela Damiani,
Renato Fanin,
Federico Silvestri,
Stefania Grimaz,
Laura Infanti,
Antonella Geromin,
Michela Cerno,
Mariagrazia Michieli,
Cristina Rinaldi,
Chiara Savignano,
Gabriella Trani,
Mauro Fiacchini, and
Michele Baccarani
From the Chair and the Division of Hematology, the Department of Bone Marrow Transplantation, University Hospital and General Hospital, Udine; and Institute of Hematology and Medical Oncology "L. and A. Seràgnoli," University of Bologna, Italy.
Although a large amount of data is available on the effects of filgrastim (granulocyte colony-stimulating factor [G-CSF]) on the mobilization of stem cells in the circulation, data concerning its effects on bone marrow (BM) harvesting is scarce and controversial. We have designed a randomized trial comparing filgrastim-mobilized peripheral blood stem cell (PBSC) transplantation with filgrastim-primed autologous bone marrow transplantation (ABMT). Fifty-five patients affected by non-Hodgkin's (n = 38) or Hodgkin's (n = 17) lymphoma, selected for autologous transplantation over a 12-month period in a single institution, were randomized 2:1 to undergo BM or PB harvest/collection after priming for 3 days with filgrastim, 16 µg/kg body weight daily subcutaneously. BM priming with G-CSF allowed the harvest of a significantly higher number of mononuclear cells (MNC) (0.53 × 108/kg, range, 0.32 to 1.40), as compared with a historical control of unprimed BM harvests (0.43 × 108 MNC/kg, range, 0.15 to 0.72, P = .001). After high-dose ablative therapy, median time to neutrophil recovery above 0.5 × 109/L was 12 days for BM and 11 days for PB (P = .219); median time to platelet recovery above 20 × 109/L was 13 days for BM and 11 days for PB (P = .242). The same number of red blood cells, platelet transfusions, and posttransplant G-CSF doses were required in the two groups of patients. Less patients (50% v 70%) became febrile in the group transplanted with mobilized PB, but days of fever/patient and days on antibiotics were overlapping. The median time spent in the hospital after reinfusion was 16.5 and 15.5 days after primed BM and primed PB, respectively (P = .134). These data suggest that in patients with lymphoma submitted to autologous transplantation, the reinfusion of filgrastim-primed BM or filgrastim-mobilized PB leads to similar results, with an advantage of only 1 day in the neutrophil recovery and 1 day on the time spent in the hospital in favor of primed PB. Either option can be chosen on the basis of the availability of a surgery room or cell separator facilities and considering the patients' characteristics and wishes.
Blood, Vol. 90 No. 1 (July 1), 1997:
pp. 36-42
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. M. Lemoli, A. de Vivo, D. Damiani, A. Isidori, M. Tani, A. Bonini, C. Cellini, A. Curti, L. Gugliotta, G. Visani, et al.
Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization
Blood,
September 1, 2003;
102(5):
1595 - 1600.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Cottler-Fox, T. Lapidot, I. Petit, O. Kollet, J. F. DiPersio, D. Link, and S. Devine
Stem Cell Mobilization
Hematology,
January 1, 2003;
2003(1):
419 - 437.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Vose, G. Sharp, W. C. Chan, C. Nichols, K. Loh, D. Inwards, R. Rifkin, P. J. Bierman, J. C. Lynch, D. D. Weisenburger, et al.
Autologous Transplantation for Aggressive Non-Hodgkin's Lymphoma: Results of a Randomized Trial Evaluating Graft Source and Minimal Residual Disease
J. Clin. Oncol.,
May 1, 2002;
20(9):
2344 - 2352.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Morton, C. Hutchins, and S. Durrant
Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells
Blood,
December 1, 2001;
98(12):
3186 - 3191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. E. Johnsen;, M. Gyger, E. Sahovic, and M. Aslam
Does Recombinant Human Granulocyte Colony-Stimulating Factor Really Prime Marrow Stem Cells in Mice and Humans?
Blood,
June 15, 1999;
93(12):
4446 - 4449.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.A. Shipp, M.D. Abeloff, K.H. Antman, G. Carroll, A. Hagenbeek, M. Loeffler, E. Montserrat, J.A. Radford, G. Salles, N. Schmitz, et al.
International Consensus Conference on High-Dose Therapy With Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: Report of the Jury
J. Clin. Oncol.,
January 1, 1999;
17(1):
423 - 423.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gyger, E. Sahovic, M. Aslam;, D. Damiani, F. Silvestri, R. Fanin, and M. Baccarani
Randomized Trial of Autologous Filgrastim-Primed Bone Marrow Transplantation Versus Filgrastim-Mobilized Peripheral Blood Stem Cell Transplantation in Lymphoma Patients
Blood,
November 1, 1998;
92(9):
3489 - 3490.
[Full Text]
[PDF]
|
|
|
|
|
